Allianz Asset Management’s Structure Therapeutics GPCR Stock Holding History

Allianz Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$415K	Sell	8,600 -3,400	-28%	-$233K	﹤0.01%	1861
2025 Q4	$835K	Buy	+12,000	New	+$490K	﹤0.01%	1747
2025 Q3	–	Sell	-11,000	Closed	-$228K	–	2027
2025 Q2	$228K	Buy	+11,000	New	+$242K	﹤0.01%	1936
2025 Q1	–	Sell	-8,800	Closed	-$239K	–	2267
2024 Q4	$239K	Hold	8,800	–	–	﹤0.01%	2068
2024 Q3	$386K	Sell	8,800 -3,000	-25%	-$116K	﹤0.01%	1921
2024 Q2	$463K	Buy	+11,800	New	+$485K	﹤0.01%	1861
2023 Q4	–	Sell	-5,500	Closed	-$277K	–	2176
2023 Q3	$277K	Buy	+5,500	New	+$177K	﹤0.01%	2079

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Allianz Asset Management's GPCR Position: Q1 2026 in Review

Allianz Asset Management reduced its Structure Therapeutics (GPCR) stake by 28% in Q1 2026, selling an estimated $233K and leaving 8,600 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #1861.

Allianz Asset Management first reported a position in GPCR in Q3 2023 and has held it in 7 quarters since. The position peaked at $835K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Allianz Asset Management held 8,600 shares of Structure Therapeutics worth $415K as of Q1 2026.
Allianz Asset Management sold 3,400 Structure Therapeutics shares in Q1 2026, an estimated $233K.
Structure Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q1 2026, its #1861 holding.
Allianz Asset Management first reported a position in Structure Therapeutics in Q3 2023 and has held it in 7 quarters since.
Allianz Asset Management's Structure Therapeutics position peaked at $835K in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.